Since the end of 2019, the coronavirus disease 2019 (COVID-19) pandemic induced by an infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) has led to millions of deaths worldwide. The unprecedented fast development of a vaccination against SARS-CoV-2 led to the approval of several vaccinations by the authorities since December 2020. Rare severe side effects are sometimes not observed during the pivotal trials but get noticed during daily clinical practice such as thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination . Thus, the description of rare side effects is urgently needed to optimize the worldwide COVID-19 vaccination campaign. Here, we report for the first time a case of myopathy with severe rhabdomyolysis and fasciitis following mRNA vaccination against SARS-CoV-2. The patient was treated in the University Hospital of Ruhr-University Bochum and gave written informed consent for the publication of her case.
A 28-year-old healthy female received the first dosage of mRNA vaccination against SARS-CoV-2 (Moderna). Five days later, she complained about muscle pain of her thigh muscles, radiating to the lower legs, accompanied by an asymmetrical weakness of the lower limbs. Seven days following vaccination, a blood test revealed marked elevation of creatine kinase and transaminases. At first presentation, she had a mild predominantly left-sided weakness of hip flexor and knee extension (MRC 4-/5 vs. MRC 4/5) with marked subcutaneous leg edema (Fig. 1a), the creatine kinase was 17,959 U/l (normal range 26–140 U/l). There had been no preceding muscular symptoms such as exercise intolerance or anesthetic reactions that might have suggested a preceding predisposition to develop rhabdomyolysis. There was also no relevant family history. Immediate workup excluded infection with hepatitis viruses, EBV or CMV. An echocardiography and a thoracic computed tomography were unremarkable. The patient was immediately treated with high volume normal saline infusion and urine alkalization. Renal function gradually worsened with a creatinine of 1.02 mg/dl (75 ml/min glomerular filtration rate according to Cockcroft–Gault) on day 5 of in-hospital treatment. Moreover, hypocalcemia of 1.97 mmol/l and moderate hypophosphatemia of 0.38 mmol/l were detected at first presentation, which gradually resolved within 4 days; parathormone was normal. Antibodies associated with myositis or myopathy were all negative (Mi-2a/b, TIF1g, MDA5, NFP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52, cN-1A). An MRI of the thigh muscles, performed on the following day, showed left-dominant edematous signal alterations with contrast enhancement of the quadriceps muscles sparing the M. rectus femoris, and diffuse subcutaneous fluid retention with contrast enhancement, suggestive of fasciitis (Fig. 1b, c). Electromyography of the left rectus muscle showed positive sharp waves and fibrillations with small and partly polyphasic motor unit potentials, compatible with an acute myopathy or myositis. The patient was treated with an i.v. cycle of 250 mg methylprednisolone over 2 days, leading to complete remission of paresis, leg pain and remission of leg edema within days, followed by oral tapering (60 mg methylprednisolone orally, tapered over 6 days). Four weeks after onset, creatine kinase was normal, the weakness and leg edema were gone, and she could do jogging again.
COVID-19 mRNA vaccine-associated side effects include pain, redness and pain at the injection site, fatigue, headache, myalgia or arthralgia [2, 3]. One case described local COVID-19 vaccine-related myopathy in the deltoid muscle with probable myositis . Recently, another case report described severe rhabdomyolysis 1 day after BioNTech/Pfizer COVID-19 vaccine administration with creatinine kinase levels of up to 22,000 U/l ; however, without signs of myopathy or fasciitis as found in the patient presented here. COVID-19 can induce a broad range of neurological symptoms including encephalitis, encephalopathy, cranial neuropathy, Guillain–Barré syndrome, and myositis/rhabdomyolysis. As of September 2020, Paliwal et al. found nine cases of myositis/rhabdomyolysis induced by natural COVID-19 disease . One report documented a patient with myopericarditis and myositis with similar subcutaneous edema and signal alterations of the thigh muscles suggestive of myositis with creatine kinase elevations  as observed in our patient following vaccination, suggesting similar pathomechanisms.
In summary, we present a new and so far unknown complication of mRNA vaccination against SARS-CoV-2. Clinicians should be vigilant especially in patients developing myalgia with paresis following COVID-19 vaccination to detect rhabdomyolysis and start treatment without delay.
Data are available from the corresponding author upon reasonable request.
Greinacher A et al (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384(22):2092–2101
Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603–2615
Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403–416
Theodorou DJ et al (2021) COVID-19 vaccine-related myositis. QJM. https://doi.org/10.1093/qjmed/hcab043
Nassar M et al (2021) COVID-19 vaccine induced rhabdomyolysis: case report with literature review. Diabetes Metab Syndr 15(4):102170
Paliwal VK et al (2020) Neuromuscular presentations in patients with COVID-19. Neurol Sci 41(11):3039–3056
Shabbir A et al (2020) Myopericarditis and myositis in a patient with COVID-19: a case report. Eur Heart J Case Rep 4(6):1–6
We thank the patient for the permission to publish her case.
Open Access funding enabled and organized by Projekt DEAL.
Conflicts of interest
The authors declare no competing interests relevant to the content of this manuscript.
Ethical standard statement
The patient provided written informed consent for the publication of the case report.
About this article
Cite this article
Faissner, S., Richter, D., Ceylan, U. et al. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. J Neurol 269, 1774–1775 (2022). https://doi.org/10.1007/s00415-021-10768-3